Effect of Macrolide Antibiotics on In-Hospital Mortality Among Acute Exacerbation of COPD Patients: A Propensity Score-Matched Analysis

References

• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Love ME, Proud D. Respiratory viral and bacterial exacerbations of COPD-the role of the airway epithelium. Cells. 2022;11(9):1416. doi:10.3390/cells11091416
   PubMed Web of Science ®Google Scholar
• Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Critical Care. 2014;18(2):208. doi:10.1186/cc13775
   PubMed Web of Science ®Google Scholar
• Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006;19(4):637–657. doi:10.1128/CMR.00051-05
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14(2):336–363. doi:10.1128/CMR.14.2.336-363.2001
   PubMed Web of Science ®Google Scholar
• Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1498–1505. doi:10.1164/ajrccm.157.5.9711044
   PubMed Web of Science ®Google Scholar
• White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58(1):73–80. doi:10.1136/thorax.58.1.73
   PubMed Web of Science ®Google Scholar
• Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020–2025. doi:10.1016/S0140-6736(01)07097-0
   PubMed Web of Science ®Google Scholar
• Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest. 2013;143(1):82–90. doi:10.1378/chest.12-0649
   PubMed Web of Science ®Google Scholar
• Roede BM, Bresser P, Prins JM, Schellevis F, Verheij TJ, Bindels PJ. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J. 2009;33(2):282–288. doi:10.1183/09031936.00088108
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303(20):2035–2042. doi:10.1001/jama.2010.672
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116(1):40–46. doi:10.1378/chest.116.1.40
   PubMed Web of Science ®Google Scholar
• Poddighe D, Aljofan M. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. Antivir Chem Chemother. 2020;28:2040206620961712. doi:10.1177/2040206620961712
   Google Scholar
• Yamaya M, Azuma A, Takizawa H, Kadota J-I, Tamaoki J, Kudoh S. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J. 2012;40(2):485. doi:10.1183/09031936.00208011
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–1508. doi:10.1164/rccm.201402-0207OC
   PubMed Web of Science ®Google Scholar
• Kiser TH, Reynolds PM, Moss M, Burnham EL, Ho PM, Vandivier RW. Impact of macrolide antibiotics on hospital readmissions and other clinically important outcomes in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease: a propensity score-matched cohort study. Pharmacotherapy. 2019;39(3):242–252. doi:10.1002/phar.2221
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Ai-Ping C, Lee K-H, Lim T-K. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest. 2005;128(2):518–524. doi:10.1378/chest.128.2.518
   PubMed Web of Science ®Google Scholar
• Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163(10):1180–1186. doi:10.1001/archinte.163.10.1180
   PubMed Web of Science ®Google Scholar
• Cao Y, Xing Z, Long H, et al. Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit. Respir Res. 2021;22(1):77. doi:10.1186/s12931-021-01657-4
   PubMed Web of Science ®Google Scholar
• Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970. doi:10.1136/thoraxjnl-2012-202103
   PubMed Web of Science ®Google Scholar
• Roche N, Zureik M, Soussan D, et al. Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. Eur Respir J. 2008;32(4):953. doi:10.1183/09031936.00129507
   PubMed Web of Science ®Google Scholar
• Asai N, Ohkuni Y, Iwasaki T, et al. Efficacy and safety of single-dose 2.0 g azithromycin in the treatment of acute exacerbation of chronic obstructive pulmonary disease. J Infect Chemother. 2011;17(6):793–798. doi:10.1007/s10156-011-0260-z
   PubMed Web of Science ®Google Scholar
• Vermeersch K, Gabrovska M, Aumann J, et al. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2019;200(7):857–868. doi:10.1164/rccm.201901-0094OC
   PubMed Web of Science ®Google Scholar
• Vermeersch K, Belmans A, Bogaerts K, et al. Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo – a post-hoc analysis of the BACE randomized controlled trial. Respir Res. 2019;20(1):237. doi:10.1186/s12931-019-1208-6
   PubMed Web of Science ®Google Scholar
• Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019;53(5):1802014. doi:10.1183/13993003.02014-2018
   PubMed Web of Science ®Google Scholar
• Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:S214–S219. doi:10.1513/AnnalsATS.201302-023AW
   PubMedGoogle Scholar
• Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–1418. doi:10.1378/chest.10-1747
   PubMed Web of Science ®Google Scholar
• Feng C, Xu M, Kang J, et al. Atypical pathogen distribution in Chinese hospitalized AECOPD patients: a multicenter cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2021;16:1699–1708. doi:10.2147/COPD.S300779
   PubMed Web of Science ®Google Scholar
• Smith D, Du Rand IA, Addy C, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. BMJ Open Respir Res. 2020;7(1):e000489. doi:10.1136/bmjresp-2019-000489
   PubMed Web of Science ®Google Scholar
• Talman S, Uzun S, Djamin RS, et al. Long-term azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:495–498. doi:10.2147/COPD.S284397
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (Columbus): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. doi:10.1016/S2213-2600(14)70019-0
   PubMed Web of Science ®Google Scholar
• Hansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019; 1. doi:10.1002/14651858.CD011825.pub2
   Web of Science ®Google Scholar
• Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369(9560):482–490. doi:10.1016/S0140-6736(07)60235-9
   PubMed Web of Science ®Google Scholar